Kos Biotechnology Partners makes a strategic investment in Golden Age Health
Golden Age Health welcomes Kos Biotechnology Partners as an investor, through its fund Kos BioVentures. Alex Tzoukas, Co-Founder and Managing Partner of Kos, will join our Board of Directors. The investment supports the expansion of GAH's commercial platform and partner portfolio in Greater China and Asia-Pacific.
Kos Biotechnology Partners makes a strategic investment in Golden Age Health
Golden Age Health welcomes Kos Biotechnology Partners as an investor, through its fund Kos BioVentures. Alex Tzoukas, Co-Founder and Managing Partner of Kos, will join our Board of Directors. The investment supports the expansion of GAH's commercial platform and partner portfolio in Greater China and Asia-Pacific.
Tenacia Biopharmaceuticals and Golden Age Health partner to commercialize ZTALMY in mainland China
Golden Age Health (Shanghai) receives exclusive rights to commercialize ZTALMY, the first approved treatment in mainland China for seizures associated with CDKL5 deficiency disorder.
Tenacia Biopharmaceuticals and Golden Age Health partner to commercialize ZTALMY in mainland China
Golden Age Health (Shanghai) receives exclusive rights to commercialize ZTALMY, the first approved treatment in mainland China for seizures associated with CDKL5 deficiency disorder.
Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China
This announcement reflects the position at its date.
Company news
2026
Patient community
Golden Age Health supports the 2026 LHON Patient Summit in Guangzhou
China's annual LHON patient gathering, organized by CORD and the Leber Youth patient community, met in Guangzhou on 6 September with support from Golden Age Health as a non-promotional educational initiative.
Golden Age Health supports the 2026 LHON Patient Summit in Guangzhou
China's annual LHON patient gathering, organized by CORD and the Leber Youth patient community, met in Guangzhou on 6 September with support from Golden Age Health as a non-promotional educational initiative.
GAH Proudly Supports the 2026 LHON Patient Summit in China
100 LHON patients treated with Raxone in seven months in Hainan
On 28 August the 100th patient received Raxone at Ruijin Hainan Hospital. Patients have come from 26 provinces, municipalities and autonomous regions of China, and from Japan and Myanmar.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
100 LHON patients treated with Raxone in seven months in Hainan
On 28 August the 100th patient received Raxone at Ruijin Hainan Hospital. Patients have come from 26 provinces, municipalities and autonomous regions of China, and from Japan and Myanmar.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Michel Vounatsos, Yossi BenAmram and Chao (Brook) Wu met the Mayor of Jinan and leaders of the Jinan Innovation Zone, Jinan Hi-Tech Holding Group and Qilu Pharmaceutical, joined by partner Innostellar, to build a two-way bridge between global and Chinese innovation.
Michel Vounatsos, Yossi BenAmram and Chao (Brook) Wu met the Mayor of Jinan and leaders of the Jinan Innovation Zone, Jinan Hi-Tech Holding Group and Qilu Pharmaceutical, joined by partner Innostellar, to build a two-way bridge between global and Chinese innovation.
First international LHON patients treated with Raxone in Hainan
On 14 July two patients from Japan and Myanmar were treated at Ruijin Hainan Hospital, the first international LHON patients treated in the Boao Lecheng International Medical Tourism Pilot Zone.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
First international LHON patients treated with Raxone in Hainan
On 14 July two patients from Japan and Myanmar were treated at Ruijin Hainan Hospital, the first international LHON patients treated in the Boao Lecheng International Medical Tourism Pilot Zone.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Golden Age Health expands into Taiwan and appoints Jeremy Lin as General Manager
Jeremy Lin brings more than 20 years of leadership at Roche, MSD, Sanofi and Novartis, and will build Golden Age Health Taiwan to expand access to rare disease and specialty therapies.
Golden Age Health expands into Taiwan and appoints Jeremy Lin as General Manager
Jeremy Lin brings more than 20 years of leadership at Roche, MSD, Sanofi and Novartis, and will build Golden Age Health Taiwan to expand access to rare disease and specialty therapies.
National Eye Care Day: more than 80 LHON patients treated with Raxone in Hainan
On China's 31st National Eye Care Day, more than 80 patients living with LHON had received Raxone through the early access program of the Boao Lecheng International Medical Tourism Pilot Zone at Ruijin Hainan Hospital.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
National Eye Care Day: more than 80 LHON patients treated with Raxone in Hainan
On China's 31st National Eye Care Day, more than 80 patients living with LHON had received Raxone through the early access program of the Boao Lecheng International Medical Tourism Pilot Zone at Ruijin Hainan Hospital.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Welltech Ventures announces its investment in Golden Age Health
Welltech Ventures welcomed Golden Age Health to its portfolio.
Golden Age Health
Investors
Welltech Ventures announces its investment in Golden Age Health
Welltech Ventures welcomed Golden Age Health to its portfolio.
Patient access
More than 50 LHON patients in China have received Raxone
Through the Boao Lecheng International Medical Tourism Pilot Zone's early access policy, more than 50 LHON patients received Raxone by the end of March.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
More than 50 LHON patients in China have received Raxone
Through the Boao Lecheng International Medical Tourism Pilot Zone's early access policy, more than 50 LHON patients received Raxone by the end of March.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Commercialization agreement for ZTALMY signed with Tenacia
Golden Age Health and Tenacia Biopharmaceuticals signed the commercialization agreement for ZTALMY, the first and only approved treatment for CDKL5 deficiency disorder in mainland China.
Commercialization agreement for ZTALMY signed with Tenacia
Golden Age Health and Tenacia Biopharmaceuticals signed the commercialization agreement for ZTALMY, the first and only approved treatment for CDKL5 deficiency disorder in mainland China.
First six LHON patients in China treated with idebenone
The ophthalmology teams of Shanghai Ruijin Hospital and Ruijin Hainan Hospital treated the first six patients on 17 January, within the Boao Lecheng International Medical Tourism Pilot Zone.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
First six LHON patients in China treated with idebenone
The ophthalmology teams of Shanghai Ruijin Hospital and Ruijin Hainan Hospital treated the first six patients on 17 January, within the Boao Lecheng International Medical Tourism Pilot Zone.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Innostellar mandates Golden Age Health to find a global partner for LX102
A second collaboration with Innostellar Biotherapeutics: Golden Age Health leads the search for a global strategic partner for LX102, a late-stage gene therapy program in wet age-related macular degeneration.
Innostellar mandates Golden Age Health to find a global partner for LX102
A second collaboration with Innostellar Biotherapeutics: Golden Age Health leads the search for a global strategic partner for LX102, a late-stage gene therapy program in wet age-related macular degeneration.
Partnership with Belief BioMed on gene therapies for hemophilia
Golden Age Health leads the search for a strategic partner to bring Belief BioMed's hemophilia B and hemophilia A gene therapy programs to global markets.
Partnership with Belief BioMed on gene therapies for hemophilia
Golden Age Health leads the search for a strategic partner to bring Belief BioMed's hemophilia B and hemophilia A gene therapy programs to global markets.
Strategic partnership with Chiesi signed at the 8th China International Import Expo
Golden Age Health and Chiesi Group signed a partnership in Shanghai to explore compliant patient access pathways for idebenone (Raxone) for LHON through the Boao Lecheng International Medical Tourism Pilot Zone in Hainan.
This announcement reflects the position at its date.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Strategic partnership with Chiesi signed at the 8th China International Import Expo
Golden Age Health and Chiesi Group signed a partnership in Shanghai to explore compliant patient access pathways for idebenone (Raxone) for LHON through the Boao Lecheng International Medical Tourism Pilot Zone in Hainan.
This announcement reflects the position at its date.
Important information: Raxone is not approved in mainland China. Its use is limited to the Boao Lecheng International Medical Tourism Pilot Zone under applicable regulations.
Memorandum of understanding signed with Mahzi Therapeutics
Golden Age Health will work with Mahzi Therapeutics, a United States gene therapy company focused on rare neurodevelopmental disorders, including on clinical development activities in China.
This announcement reflects the position at its date.
Memorandum of understanding signed with Mahzi Therapeutics
Golden Age Health will work with Mahzi Therapeutics, a United States gene therapy company focused on rare neurodevelopmental disorders, including on clinical development activities in China.
This announcement reflects the position at its date.
Second patient treated with LX101 gene therapy in Hainan
A second patient received Innostellar's LX101 gene therapy for inherited retinal dystrophies in Hainan, with more patients planned in the coming months.
This announcement reflects the position at its date.
Second patient treated with LX101 gene therapy in Hainan
A second patient received Innostellar's LX101 gene therapy for inherited retinal dystrophies in Hainan, with more patients planned in the coming months.
This announcement reflects the position at its date.
Exclusive 10-year partnership with Innostellar for LX101 in mainland China
Golden Age Health and Innostellar Biotherapeutics signed an exclusive 10-year partnership to develop and commercialize LX101 gene therapy for inherited retinal dystrophies due to RPE65 mutation.
This announcement reflects the position at its date.
Exclusive 10-year partnership with Innostellar for LX101 in mainland China
Golden Age Health and Innostellar Biotherapeutics signed an exclusive 10-year partnership to develop and commercialize LX101 gene therapy for inherited retinal dystrophies due to RPE65 mutation.
This announcement reflects the position at its date.
Jingyan Song (medical marketing), Yanmei Sun and Leling Han join Golden Age Health in China, each with more than 20 years in the pharmaceutical industry.
This announcement reflects the position at its date.
Jingyan Song (medical marketing), Yanmei Sun and Leling Han join Golden Age Health in China, each with more than 20 years in the pharmaceutical industry.
This announcement reflects the position at its date.
